Company / Accounts Receivable
Viridian Therapeutics, Inc.\DE Accounts Receivable History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$108.0K
FY2019
5-year range
-
FY2016-FY2019
Trend
+350.0%
vs FY2018
Sector context
#112 of 113
Health Care
What the data says
Accounts Receivable changed +350% YoY in FY2019, a notable deviation from the 3-year average annual change of +2477%.
Based on SEC 10-K filings.
$108,000 in FY2019 with a 3-year CAGR of +75.4%.
Declined from $1M to $108,000 over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +75.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 113This company $108.0K Sector average $1.1B
▼
-100.0% below sector average
Key checks
Key Insights
- 3-year CAGR of +75.4%, indicating consistent growth.
- In FY2019, accounts receivable increased 350.0% year-over-year.
- Ranks #112 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | $108.0K | +350.0% |
| FY2018 | $24.0K | -98.4% |
| FY2017 | $1.5M | +7180.0% |
| FY2016 | $20.0K | -94.9% |
As of FY2019 · SEC 10-K · Updated Jun 30, 2026